Anifrolumab, a relatively emerging monoclonal antibody, is creating considerable interest within the scientific community as a viable option for various inflammatory ailments. This unique medication targets the https://esmeeiwmy996537.aboutyoublog.com/52291615/anifrolumab-a-novel-therapy-for-autoimmune-conditions